Stories

In today’s rapidly evolving treatment landscape the approval of a medicine is no longer the finish line; it’s just the beginning. Real world evidence (RWE), post-hoc analyses and structured Phase IV studies all offer new opportunities for scientific learning. At Ipsen, we’re committed to pursuing the unanswered questions, generating robust evidence that goes beyond medicine development, which provides broader long-term evidence-based perspectives for the communities we serve. 

A diagnosis is supposed to be the end of the uncertainty. For some families, it is also the moment they realize there is nothing more medicine can offer. Loubna Ouriaghli, Head of Government Affairs & Policy at Ipsen, witnessed that moment with her own mother who was diagnosed with a rare disease.  She saw the symptoms appear one by one, the years it took to finally have an answer and the silence that followed when that answer came with no treatment. 

We’re excited to be at the European Association for the Study of the Liver (EASL) Congress 2026, Europe’s largest event dedicated to liver health where doctors, scientists, allied health professionals, patients, and industry partners come together to share knowledge, highlight scientific breakthroughs, and build meaningful connections.

There are moments that stay with you. Not because of a single slide or headline, but because you can feel something changing. Expectations shift. Standards rise. A new chapter begins. 

Ipsen’s 2025 Integrated Annual report report is now available on Ipsen.com. This essential reference document brings together key information and insights into the major developments in 2025 and what lies ahead.